Aoxiang Pharmaceutical: Wholly owned subsidiary obtains the drug registration certificate for Entecavir tablets

Aoxiang Pharmaceutical announces that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., recently received the drug registration certificate for Entecavir tablets issued by the National Medical Products Administration. Entecavir tablets are mainly used to treat chronic hepatitis B infections with active viral replication and persistent elevation of serum transaminases.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin